GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » Net Issuance of Preferred Stock

NVZMF (Novonesis (Novozymes) B) Net Issuance of Preferred Stock : $0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Novonesis (Novozymes) B's net issuance of preferred for the three months ended in Mar. 2025 was $0 Mil. The number is 0, which means that Novonesis (Novozymes) B has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Novonesis (Novozymes) B's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was $0 Mil.


Novonesis (Novozymes) B Net Issuance of Preferred Stock Historical Data

The historical data trend for Novonesis (Novozymes) B's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Net Issuance of Preferred Stock Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novonesis (Novozymes) B Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novonesis (Novozymes) B Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

From GuruFocus

Q1 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Half Year 2024 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 08-29-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Q2 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024